Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hikma Overtakes Fresenius In US Injectables

Injectables Growth Across Regions In 2021 Accompanies Expansion Through Acquisitions

Mar 02 2022

• By David Wallace

Competition winners podium 1 2 3 — Hikma has jumped into second place in US injectables volumes • Source: Enrico Mantegazza / Alamy Stock Photo

Related Content

Fresenius Kabi: No Launches From US Melrose Park Facility In 2021

Feb 25 2021

Hikma Adds Remsima SC To Celltrion MENA Collaboration

Feb 09 2022

Hikma Warns Of Renewed Pricing Pressure On US Generics

Mar 03 2022

Hikma Seeks To Meet Demand For 503B Compounding In US

Jan 25 2022

Hikma Highlights Long-Term Importance Of Biosimilars

Jan 24 2022

Hikma Buys Teligent Assets To Expand Into Canada

Jan 17 2022

Related Companies

Hikma Pharmaceuticals plc

Additional Topics

United States Sales & Earnings Strategy Generic Drugs Biosimilars BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.